Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that Dr. Simon Pimstone, CEO, will participate in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that Dr. Simon Pimstone, CEO, will participate in two upcoming virtual investor conferences. The William Blair Biotech Focus Conference 2020 is scheduled for August 6, 2020, at 12:00 pm ET, focusing on new therapies for epilepsy. The Wedbush PacGrow Healthcare Conference will take place on August 11, 2020, at 3:30 pm ET. All presentations will be available for replay on Xenon's website for 30 days following the events.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +1.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences:
- William Blair Biotech Focus Conference 2020 | Panel 4: New Therapies Impacting the Epilepsy Treatment Landscape on Thursday, August 6, 2020 at 12:00 pm ET
- 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 3:30 pm ET
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at www.xenon-pharma.com. All webcasts will be posted for replay following the event for 30 days.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.